You are here

TSRL, INC.

Company Information
Address
540 AVIS DR STE A
ANN ARBOR, MI 48108-7906
United States



Information

UEI: TP74UMNGJDJ1

# of Employees: 9


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Improving Absorption and Targeting of Antiviral Drugs

    Amount: $1,000,000.00

    DESCRIPTION (provided by applicant): With recent unsettling events foreshadowing an increased sense of urgency, NIAID has targeted research and development of therapeutics, vaccines, adjuvants/immunos ...

    SBIRPhase II2007Department of Health and Human Services National Institutes of Health
  2. Vidarabine Prodrugs as Anti-Pox Virus Agents

    Amount: $297,813.00

    DESCRIPTION (provided by applicant): The Working Group for Civilian Biodefense has identified smallpox as one of the most serious biological agents that could cause disease and deaths in sufficient nu ...

    SBIRPhase I2007Department of Health and Human Services National Institutes of Health
  3. Enhancing Thrombostatin's Oral Delivery

    Amount: $274,452.00

    DESCRIPTION (provided by applicant): The long term objective of the project is to develop an orally bioavailable drug for treatment of individuals with acute coronary syndromes (ACS) and also individu ...

    SBIRPhase I2006Department of Health and Human Services National Institutes of Health
  4. Bile acid conjugates to improve the oral bioavailability of anti-influenza drugs

    Amount: $299,314.00

    DESCRIPTION (provided by applicant): With the concern for an avian influenza pandemic increasing, there is a need to develop antiviral therapies with improved bioavailability. We are developing an enh ...

    SBIRPhase I2006Department of Health and Human Services National Institutes of Health
  5. Improving Absorption and Targeting of Antiviral Drugs

    Amount: $926,954.00

    DESCRIPTION (provided by investigator): With recent unsettling events foreshadowing an increased sense of urgency, NIAID has targeted research and development of therapeutics, vaccines, adjuvants/imm ...

    SBIRPhase I2003Department of Health and Human Services National Institutes of Health
  6. Oral Delivery of Thrombostatin

    Amount: $205,333.00

    DESCRIPTION (provided by applicant): The hypothesis of this proposal is that the di- or tri-peptide transporter in the gastrointestinal tract can be used as a means to absorb orally delivered peptides ...

    SBIRPhase I2003Department of Health and Human Services National Institutes of Health
  7. MODELS FOR SCREENING INTESTINAL TRANSPORTER PRODRUGS

    Amount: $188,924.00

    DESCRIPTION (provided by applicant): Recently, it has been shown that a variety of drugs require carrier-mediated transport (e.g., the human dipeptide transporter or hpepT1) in order to cross the cel ...

    SBIRPhase I2002Department of Health and Human Services National Institutes of Health
  8. DEVELOPMENT OF AN ORAL ANTHRAX VACCINE

    Amount: $203,609.00

    DESCRIPTION (provided by applicant): Of the numerous biological agents that may be used as weapons, the Working Group on Civilian Biodefense has identified Bacillus anthracis as one of the most seriou ...

    SBIRPhase I2002Department of Health and Human Services National Institutes of Health
  9. N/A

    Amount: $180,297.00

    N/A

    SBIRPhase I2000Department of Health and Human Services National Institutes of Health
  10. ORAL DELIVERY OF ENCAPSULATED MULTIMERIC AIDS VACCINES

    Amount: $155,244.00

    Not Available This Phase I SBIR proposal is aimed at developing a design capability and comprehensive set of simulation tools for exploring the feasibility and making a realistic assessment of the po ...

    SBIRPhase I1999Department of Health and Human Services
US Flag An Official Website of the United States Government